beremagene geperpavec Vyjuvek

Selected indexed studies

• Beremagene Geperpavec: First Approval. (Drugs, 2023) [PMID:37432558]
• Herpes simplex virus gene therapy for dystrophic epidermolysis bullosa (DEB). (Cell, 2023) [PMID:37595560]
• Developing CRISPR-Based Therapies for Epidermolysis Bullosa: A Comprehensive Review of Current Strategies. (Drugs, 2026) [PMID:41731282]

_Worker-drafted node — pending editorial review._